Ustekinumab not checked

Johnson & Johnson (Janssen) · CNTO1275 · CNTO 1275

FollowEvery change as it happens, and a Monday email
Stage
in the US
Next date
Phase 3 trial completes
Trials
11 active
37 in total · 16 in the EU
Targets
 

What this is

How it works
An antibody: a lab-made immune protein built to latch onto one target in the body.-mab: monoclonal antibodies WHO name stem
How it’s given
“Ustekinumab will be administered by IV infusion and SC injection.”In the company’s words, NCT03466411 on ClinicalTrials.gov
Tested for
Plaque Psoriasis, Crohn Disease, Colitis, Ulcerative, Arthritis, Psoriatic, Crohn's Disease
Main trialPhase 3
“The main purpose of this study is to assess how well JNJ-77242113 works when compared to placebo and ustekinumab in participants with moderate to severe plaque psoriasis.”In the company’s words, NCT06934226 on ClinicalTrials.gov
Other names
STELARA · CNTO1275 · CNTO 1275

Other drugs for Plaque Psoriasis

All 41 drugs for Plaque Psoriasis

Copies tested against it7

Other companies’ versions, mostly cheaper copies for when the patent ends

Coming up1

Changes0

Last 90 days

No changes yet. We started recording changes on 6 Nov 2026.

Trials37

TrialPhaseCompletesWhat it tests
Phase 3Active, not recruiting 17 Nov 2025 A Study to Assess Efficacy and Safety of JNJ-77242113 Compared to Placebo and Ustekinumab in Participants With Moderate to Severe Plaque Psoriasis
Phase 3Active, not recruiting 29 Sep 2027 A Long-term Extension Study of Ustekinumab in Pediatric Participants
Phase 2/3Active, not recruiting 20 Oct 2023 A Study of the Efficacy and Safety of Guselkumab in Participants With Moderately to Severely Active Crohn's Disease
Phase 4Completed 18 May 2025 A Study of Ustekinumab (STELARA) in Chinese Participants With Moderately to Severely Active Crohn's Disease
Phase 3Completed 10 Jun 2015 A Study to Evaluate the Safety and Efficacy of Ustekinumab Maintenance Therapy in Patients With Moderately to Severely Active Crohn's Disease (IM-UNITI)
Phase 3Terminated 22 Mar 2017 A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNFα Naive Participants With Active Radiographic Axial Spondyloarthritis
Phase 3Terminated 31 Aug 2017 A Study to Evaluate the Efficacy and Safety of Ustekinumab in the Treatment of Anti-TNF(Alpha) Refractory Participants With Active Radiographic Axial Spondyloarthritis
Phase 3Completed Dec 2017 An Efficacy, Safety, and Pharmacokinetics Study of Subcutaneously Administered Ustekinumab in the Treatment of Moderate to Severe Chronic Plaque Psoriasis in Pediatric Participants Greater Than or Equal to 6 to Less Than 12 Years of Age
Phase 3Completed 10 Aug 2018 A Study to Evaluate the Safety and Efficacy of Ustekinumab Induction and Maintenance Therapy in Participants With Moderately to Severely Active Ulcerative Colitis
Phase 3Completed 30 Apr 2020 Study of Treat to Target Versus Routine Care Maintenance Strategies in Crohn's Disease Patients Treated With Ustekinumab
Phase 3Terminated 5 Nov 2020 A Study of Ustekinumab in Participants With Active Systemic Lupus Erythematosus
Phase 3Completed 15 Dec 2020 Safety and Efficacy of Adalimumab Versus Ustekinumab for One Year
Phase 3Terminated 24 Jan 2022 A Study of Ustekinumab in Participants With Active Polymyositis and Dermatomyositis Who Have Not Adequately Responded to One or More Standard-of-care Treatments
Phase 3Withdrawn 31 Jan 2022 A Study of Ustekinumab in Chinese Participants With Active Systemic Lupus Erythematosus
Phase 3Completed 19 Aug 2022 A Study to Evaluate Efficacy and Safety of Ustekinumab Re-induction Therapy in Participants With Moderately to Severely Active Crohn's Disease
Phase 3Terminated 25 May 2023 A Study of Ustekinumab in Participants With Takayasu Arteritis (TAK)
Phase 3Completed 28 Nov 2024 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Crohn's Disease
Phase 3Completed 8 May 2025 A Study of Ustekinumab in Pediatric Participants With Moderately to Severely Active Ulcerative Colitis (UC)
Phase 3Completed 12 Jan 2026 A Study of Ustekinumab or Guselkumab in Pediatric Participants With Active Juvenile Psoriatic Arthritis
Phase 2Completed 31 May 2016 Efficacy and Safety Study of Guselkumab in the Treatment of Participants With Active Psoriatic Arthritis (PsA)
Phase 2Completed 10 Dec 2020 Safety and Efficacy Study of JNJ-64304500 in Participants With Moderately to Severely Active Crohn's Disease
Phase 2Withdrawn 24 May 2023 A Study of JNJ-64304500 as Add-on Therapy in Participants With Active Crohn's Disease
Phase 1Completed 19 Sep 2018 A Pharmacokinetic Study of Ustekinumab in Pediatric Subjects With Moderately to Severely Active Crohn's Disease
Phase 1Completed 31 Dec 2020 Study of Guselkumab and Ustekinumab Following a Single Intravenous or Subcutaneous Administration in Healthy Chinese Participants
Phase 1Terminated 22 Nov 2021 A Study to Evaluate the Effect of Ustekinumab on Cytochrome P450 Enzyme Activities Following Induction and Maintenance Dosing in Participants With Active Crohn's Disease or Ulcerative Colitis
Phase 1Completed 7 Jan 2022 A Study to Assess the Bioequivalence of Ustekinumab by Two Different Injection Devices in Healthy Participants
Phase 1Completed 26 Jan 2024 A Study of Ustekinumab in Pediatric Participants (U-POPS) With Juvenile Psoriatic Arthritis or Psoriasis
Phase 4Authorised not given Prevention of postoperative endoscopic recurrence with endoscopy-driven versus systematic biological therapy: a randomized, multicentre, parallel group pragmatic non-inferiority trial in adult patients with Crohn’s disease undergoing an ileocolonic resection with ileocolonic anastomosis
Phase 2Authorised not given Comparison of ustekinumab, infliximab and COMBinatiOn therapy in moderately-to-severely active Ulcerative Colitis – the head-to-head COMBO-UC trial.
Phase 2Authorised not given Evaluation of the efficacy and safety of dual biological therapy in patients with refractory Crohn's disease resistant to induction (FLAMING).
Phase 3Authorised not given A prospective, randomized, controlled, open label, assessor-blinded, parallel-group Phase III clinical trial to evaluate the impact of tapering systemic immunosuppressive therapy in a treat-to-target approach on maintaining minimal disease activity in adult subjects with psoriatic arthritis
Phase 2Ended not given PIMOC - Personalized targeted therapies in inflammatory complex multi organ disease
Phase 3/4Ended not given An Open-Label Extension and long-term efficacy and safety monitoring study of patients with Crohn's disease previously included in the loss of RESponse to Ustekinumab treated by dose Escalation study (REScUE-OLE)
Phase 2Authorised not given BOOSTERS - BiOlogics in FOlliculitis decalvanS : an adaptaTivE tRial reSearch
Phase 3Authorised not given FirST lines of biologics in pAtients with ulceRaTivE colitis: a Randomised controlled trial
Phase 4Authorised not given MOVE-IT: MOdel-Informed Precision Dosing of Ustekinumab and VEdolizumab in Inflammatory Bowel Disease - An Independant Randomized Controlled Trial
Phase 2Authorised not given Giving Upfront Anti-p40 to Reduce toxicity from Dual Immune Checkpoint Inhibition in MESOthelioma
A trial in both registries shows both numbers.

About

Sources
ClinicalTrials.gov updated 18 Nov 2026 · EU trials register (CTIS) updated 18 Nov 2026 · openFDA updated 17 Nov 2026

Follow Ustekinumab

Following is part of Solo: you see every change to Ustekinumab the day it happens.

Solo

$49a month, excl. VAT

  • Follow up to 5 landscapes, companies or drugs
  • Every change, the day it happens
  • A Monday email with the week’s changes
Choose Solo

Free

$0no card

  • One landscape of your own, in full
  • The top 10 of everything else
Sign up free

Have an account? Sign in